Cancer and Metastasis Reviews最新文献

筛选
英文 中文
Lost at SCLC: a review of potential platinum sensitizers. 迷失在 SCLC:潜在铂敏化剂综述。
IF 4.4 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-08-23 DOI: 10.1007/s10555-024-10207-5
Bryan Oronsky, Nacer Abrouk, Li Mao, Yunle Shen, Xiaohui Wang, Luyang Zhao, Scott Caroen, Tony Reid
{"title":"Lost at SCLC: a review of potential platinum sensitizers.","authors":"Bryan Oronsky, Nacer Abrouk, Li Mao, Yunle Shen, Xiaohui Wang, Luyang Zhao, Scott Caroen, Tony Reid","doi":"10.1007/s10555-024-10207-5","DOIUrl":"10.1007/s10555-024-10207-5","url":null,"abstract":"<p><p>The expression \"lost at sea\" means to be confused or perplexed. By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a \"recalcitrant cancer.\" Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1573-1578"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. GLP-1R 激动剂对肥胖、糖尿病和癌症三联症的影响。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-05-27 DOI: 10.1007/s10555-024-10192-9
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, Aranka Brockmueller, Mehdi Shakibaei, Dietrich Büsselberg
{"title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer.","authors":"Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, Aranka Brockmueller, Mehdi Shakibaei, Dietrich Büsselberg","doi":"10.1007/s10555-024-10192-9","DOIUrl":"10.1007/s10555-024-10192-9","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1297-1314"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of MARCH E3 ubiquitin ligases in cancer development. MARCH E3 泛素连接酶在癌症发展中的作用。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI: 10.1007/s10555-024-10201-x
Abhayananda Behera, Deepanshi Sachan, Ganesh Kumar Barik, Aramati Bindu Madhava Reddy
{"title":"Role of MARCH E3 ubiquitin ligases in cancer development.","authors":"Abhayananda Behera, Deepanshi Sachan, Ganesh Kumar Barik, Aramati Bindu Madhava Reddy","doi":"10.1007/s10555-024-10201-x","DOIUrl":"10.1007/s10555-024-10201-x","url":null,"abstract":"<p><p>Membrane-associated RING-CH (MARCH) E3 ubiquitin ligases, a family of RING-type E3 ubiquitin ligases, have garnered increased attention for their indispensable roles in immune regulation, inflammation, mitochondrial dynamics, and lipid metabolism. The MARCH E3 ligase family consists of eleven distinct members, and the dysregulation of many of these members has been documented in several human malignancies. Over the past two decades, extensive research has revealed that MARCH E3 ligases play pivotal roles in cancer progression by ubiquitinating key oncogenes and tumor suppressors and orchestrating various signaling pathways. Some MARCH E3s act as oncogenes, while others act as tumor suppressors, and the majority of MARCH E3s play both oncogenic and tumor suppressive roles in a context-dependent manner. Notably, there is special emphasis on the sole mitochondrial MARCH E3 ligase MARCH5, which regulates mitochondrial homeostasis within cancer cells. In this review, we delve into the diverse functions of MARCH E3 ligases across different cancer types, shedding light on the underlying molecular mechanisms mediating their effects, their regulatory effects on cancer and their potential as therapeutic targets.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1257-1277"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular and cellular mechanisms of chemoresistance in paediatric pre-B cell acute lymphoblastic leukaemia. 小儿前 B 细胞急性淋巴细胞白血病化疗抗药性的分子和细胞机制。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-08-05 DOI: 10.1007/s10555-024-10203-9
Caleb B Lill, Stephen Fitter, Andrew C W Zannettino, Kate Vandyke, Jacqueline E Noll
{"title":"Molecular and cellular mechanisms of chemoresistance in paediatric pre-B cell acute lymphoblastic leukaemia.","authors":"Caleb B Lill, Stephen Fitter, Andrew C W Zannettino, Kate Vandyke, Jacqueline E Noll","doi":"10.1007/s10555-024-10203-9","DOIUrl":"10.1007/s10555-024-10203-9","url":null,"abstract":"<p><p>Paediatric patients with relapsed B cell acute lymphoblastic leukaemia (B-ALL) have poor prognosis, as relapse-causing clones are often refractory to common chemotherapeutics. While the molecular mechanisms leading to chemoresistance are varied, significant evidence suggests interactions between B-ALL blasts and cells within the bone marrow microenvironment modulate chemotherapy sensitivity. Importantly, bone marrow mesenchymal stem cells (BM-MSCs) and BM adipocytes are known to support B-ALL cells through multiple distinct molecular mechanisms. This review discusses the contribution of integrin-mediated B-ALL/BM-MSC signalling and asparagine supplementation in B-ALL chemoresistance. In addition, the role of adipocytes in sequestering anthracyclines and generating a BM niche favourable for B-ALL survival is explored. Furthermore, this review discusses the role of BM-MSCs and adipocytes in promoting a quiescent and chemoresistant B-ALL phenotype. Novel treatments which target these mechanisms are discussed herein, and are needed to improve dismal outcomes in patients with relapsed/refractory disease.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1385-1399"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis. 组织因子通路抑制因子-2(TFPI-2)--癌症和转移中一个未被充分重视的参与者。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-08-17 DOI: 10.1007/s10555-024-10205-7
Marek Z Wojtukiewicz, Marta Mysliwiec, Anna Tokajuk, Joanna Kruszewska, Barbara Politynska, Anmbreen Jamroze, Anna M Wojtukiewicz, Dean G Tang, Kenneth V Honn
{"title":"Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.","authors":"Marek Z Wojtukiewicz, Marta Mysliwiec, Anna Tokajuk, Joanna Kruszewska, Barbara Politynska, Anmbreen Jamroze, Anna M Wojtukiewicz, Dean G Tang, Kenneth V Honn","doi":"10.1007/s10555-024-10205-7","DOIUrl":"10.1007/s10555-024-10205-7","url":null,"abstract":"<p><p>The coagulation system is known to play an important role in cancer development and metastasis, but the precise mechanisms by which it does so remain incompletely understood. With this in mind, we provide an updated overview of the effects of TFPI-2, a protease inhibitor, on cancer development and metastasis. TFPI-2 interacts with the thrombin cascade and also employs other mechanisms to suppress cancer growth and dissemination, which include extracellular matrix stabilization, promotion of caspase-mediated cell apoptosis, inhibition of angiogenesis and transduction of intracellular signals. Down-regulation of TFPI-2 expression is well documented in numerous types of neoplasms, mainly via promoter methylation. However, the exact role of TFPI-2 in cancer progression and possible approaches to up-regulate TFPI-2 expression warrant further studies. Strategies to reactivate TFPI-2 may represent a promising direction for future anticancer studies and therapy development.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1185-1204"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T-cells for pediatric solid tumors: where to go from here? CAR T 细胞治疗小儿实体瘤:何去何从?
IF 4.4 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s10555-024-10214-6
Tina Trautmann, Natalia Yakobian, Rosa Nguyen
{"title":"CAR T-cells for pediatric solid tumors: where to go from here?","authors":"Tina Trautmann, Natalia Yakobian, Rosa Nguyen","doi":"10.1007/s10555-024-10214-6","DOIUrl":"10.1007/s10555-024-10214-6","url":null,"abstract":"<p><p>Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors. Especially in the pediatric population, pre- and post-treatment biopsies are rarely performed due to ethical reasons, and thus, our understanding is still very limited regarding the mechanisms in the tumor microenvironment by which tumor cells exclude effectors and attract immune-suppressive cells. Nevertheless, based on the principles that are known, current T-cell engineering has leveraged some of these processes and created more potent CAR T-cells. The recent discovery of new oncofetal antigens and progress made in CAR design have expanded the potential pool of candidate antigens for therapeutic development. The most promising approaches to enhance CAR T-cells are novel CAR gating strategies, creative ways of cytokine delivery to the TME without enhancing systemic toxicity, and hijacking the chemokine axis of tumors for migratory purposes. With these new modifications, the next step in the era of CAR T-cell development will be the clinical validation of these promising preclinical findings.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1445-1461"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T cells in solid tumors and metastasis: paving the way forward. CAR T 细胞在实体瘤和转移中的应用:铺平道路。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s10555-024-10213-7
Camilla Sirini, Laura De Rossi, Marta Angiola Moresco, Monica Casucci
{"title":"CAR T cells in solid tumors and metastasis: paving the way forward.","authors":"Camilla Sirini, Laura De Rossi, Marta Angiola Moresco, Monica Casucci","doi":"10.1007/s10555-024-10213-7","DOIUrl":"10.1007/s10555-024-10213-7","url":null,"abstract":"<p><p>CAR T cell therapy, hailed as a breakthrough in cancer treatment due to its remarkable outcomes in hematological malignancies, encounters significant hurdles when applied to solid tumors. While notable responses to CAR T cells remain sporadic in these patients, challenges persist due to issues such as on-target off-tumor toxicity, difficulties in their trafficking and infiltration into the tumor, and the presence of a hostile and immunosuppressive microenvironment. This review aims to explore recent endeavors aimed at overcoming these obstacles in CAR T cell therapy for solid tumors. Specifically, we will delve into promising strategies for enhancing tumor specificity through antigen targeting, addressing tumor heterogeneity, overcoming physical barriers, and counteracting the immune-suppressive microenvironment.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1279-1296"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrical excitability of cancer cells-CELEX model updated. 癌细胞的电兴奋性--CELEX 模型更新。
IF 4.4 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI: 10.1007/s10555-024-10195-6
Mustafa B A Djamgoz
{"title":"Electrical excitability of cancer cells-CELEX model updated.","authors":"Mustafa B A Djamgoz","doi":"10.1007/s10555-024-10195-6","DOIUrl":"10.1007/s10555-024-10195-6","url":null,"abstract":"<p><p>The normal functioning of every cell in the body depends on its bioelectric properties and many diseases are caused by genetic and/or epigenetic dysregulation of the underlying ion channels. Metastasis, the main cause of death from cancer, is a complex multi-stage process in which cells break away from a primary tumour, invade the surrounding tissues, enter the circulation by encountering a blood vessel and spread around the body, ultimately lodging in distant organs and reproliferating to form secondary tumours leading to devastating organ failure. Such cellular behaviours are well known to involve ion channels. The CELEX model offers a novel insight to metastasis where it is the electrical excitation of the cancer cells that is responsible for their aggressive and invasive behaviour. In turn, the hyperexcitability is underpinned by concomitant upregulation of functional voltage-gated sodium channels and downregulation of voltage-gated potassium channels. Here, we update the in vitro and in vivo evidence in favour of the CELEX model for carcinomas. The results are unequivocal for the sodium channel. The potassium channel arm is also broadly supported by existing evidence although these data are complicated by the impact of the channels on the membrane potential and consequent secondary effects. Finally, consistent with the CELEX model, we show (i) that carcinomas are indeed electrically excitable and capable of generating action potentials and (ii) that combination of a sodium channel inhibitor and a potassium channel opener can produce a strong, additive anti-invasive effect. We discuss the possible clinical implications of the CELEX model in managing cancer.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1579-1591"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies. 肽治疗微生物诱发的癌症:最新治疗策略及其先进技术。
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-15 DOI: 10.1007/s10555-024-10197-4
Ziqi Lin, Yehuda G Assaraf, Hang Fai Kwok
{"title":"Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies.","authors":"Ziqi Lin, Yehuda G Assaraf, Hang Fai Kwok","doi":"10.1007/s10555-024-10197-4","DOIUrl":"10.1007/s10555-024-10197-4","url":null,"abstract":"<p><p>Cancer is a significant global health concern associated with multiple distinct factors, including microbial and viral infections. Numerous studies have elucidated the role of microorganisms, such as Helicobacter pylori (H. pylori), as well as viruses for example human papillomavirus (HPV), hepatitis B virus (HBV), and hepatitis C virus (HCV), in the development of human malignancies. Substantial attention has been focused on the treatment of these microorganism- and virus-associated cancers, with promising outcomes observed in studies employing peptide-based therapies. The current paper provides an overview of microbe- and virus-induced cancers and their underlying molecular mechanisms. We discuss an assortment of peptide-based therapies which are currently being developed, including tumor-targeting peptides and microbial/viral peptide-based vaccines. We describe the major technological advancements that have been made in the design, screening, and delivery of peptides as anticancer agents. The primary focus of the current review is to provide insight into the latest research and development in this field and to provide a realistic glimpse into the future of peptide-based therapies for microbe- and virus-induced neoplasms.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1315-1336"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms.
IF 7.7 2区 医学
Cancer and Metastasis Reviews Pub Date : 2024-12-01 DOI: 10.1007/s10555-024-10228-0
Tyce J Kearl, Fateeha Furqan, Nirav N Shah
{"title":"CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms.","authors":"Tyce J Kearl, Fateeha Furqan, Nirav N Shah","doi":"10.1007/s10555-024-10228-0","DOIUrl":"10.1007/s10555-024-10228-0","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T cells are an exciting curative intent approach to the treatment of non-Hodgkin lymphomas (NHLs). Several products have received FDA approval for 2nd or 3rd line indications, and studies are underway for their use earlier in the disease course. These CAR T cells are ex vivo manufactured autologous cell products that specifically target tumor antigens to optimize tumor specificity and minimize off-tumor side effects-in NHLs, this is typically achieved by targeting B-cell antigens. Engagement of the CAR and corresponding antigen is designed to result in T-cell activation and subsequent tumor clearance. While curative for many NHL patients, too many patients fail to respond to or relapse following CAR T-cell treatment, and salvage options post CAR T-cell therapy are limited. Treatment failures occur because of myriad resistance mechanisms including CAR T-cell dysfunction, generalized immune dysregulation, and intrinsic tumor resistance. Focusing on patients with NHL, we review the clinical outcomes of CAR T-cell therapy and the major resistance mechanisms that lead to poor outcomes. We also review the many innovative and encouraging strategies that are being developed to improve CAR T-cell therapy for NHL.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":"44 1","pages":"12"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信